Combined influenza-AIDS vaccines and mucosal vaccinations
|Professor Stephen Kentfirstname.lastname@example.org||+61 3 8344 9939||View page|
Influenza and HIV are both serious global pathogens. Can a single vaccine be designed to cover both viruses?! Recent advances in reverse genetic techniques allow insertion of foreign antigens into live influenza viruses. Further, live attenuated influenza vaccines are now highly effective vaccines. Together with our collaborators we are designing recombinant influenza vaccines with inserted SIV antigens to test as a combined Influenza-AIDS vaccine. An advantage of this strategy is that as a mucosal virus, there is a strong likelihood that immunity at mucosal surfaces, where HIV is first encountered, can be induced with this approach. Exciting data suggest this approach has great potential to induce T cell immunity although escape from single CTL epitopes is a significant barrier. We have recently generated Flu-HIV vaccines that express an expanded range of HIV antigens104 * and show great promise for the induction of resident memory T cells in mice. 238 *
Figure 1: FACS plots of SIV KP9-specific CD8+ T cells in blood before and 7 days after Flu-SIV infection
* superscript number links to a specific publication in the chronological listing on Stephen's blog
Dr Hyon-Xhi-Tan, Dr Adam Wheatley
NHMRC Project and program grant funding.
Faculty Research Themes
School Research Themes
For further information about this research, please contact the research group leader.